Skip to main content
Premium Trial:

Request an Annual Quote

Tripos Completes Purchase of Optive Research for $7.9M

NEW YORK, Jan. 5 (GenomeWeb News) - Tripos has completed the acquisition of Optive Research, a discovery informatics software developer, for roughly $7.9 million in stock and cash, the St. Louis-based company said today.


Under the agreement, Optive shareholders will receive 599,521 shares of Tripos common stock, worth about $3.18 million at the end of trading yesterday, and $4.75 million in cash. The cash portion of the purchase was funded by a $4 million investment by Horizon Technology Finance and Sand Hill Capital through the issuance of $3.5 million of subordinated debt, 111,606 shares of common stock, and warrants to purchase 156,250 shares of common stock.


Tripos expects the transaction to contribute to its operating income in 2005 and become accretive to net income by 2006.


Tripos already distributes five of 15 software products from Optive, a 2002 spinout from the University of Texas at Austin.

The Scan

Shape of Them All

According to BBC News, researchers have developed a protein structure database that includes much of the human proteome.

For Flu and More

The Wall Street Journal reports that several vaccine developers are working on mRNA-based vaccines for influenza.

To Boost Women

China's Ministry of Science and Technology aims to boost the number of female researchers through a new policy, reports the South China Morning Post.

Science Papers Describe Approach to Predict Chemotherapeutic Response, Role of Transcriptional Noise

In Science this week: neural network to predict chemotherapeutic response in cancer patients, and more.